2013-09-09 18:04:03 -
Deinove confirmS THE AWARD OF ITS European PATENT
"USE OF DEINOCOCCUS FOR THE production OF BIOENERGY"
DEINOVE's intellectual property is further strengthened with the award of a
major patent, which is jointly held with the French National Centre for
Scientific Research (CNRS) and the University of Montpellier 1, who granted an
exclusive worldwide license to DEINOVE, to produce biofuels or green chemistry
molecules from biomass, including various plant materials, agricultural residues
and organic or municipal sold waste.
Paris, 9 September 2013 - Deinove (Alternext Paris: ALDEI), a cleantech company
that designs, develops and markets the next generation of industrial processes
based on deinococcus bacteria, has announced that the award of its major patent
EP2209900 was published in issue 13/23 of the European Patent Bulletin on 5 June
The invention involves the pioneering
use of deinococcus bacteria to produce
biofuels (biodiesel and bioalcohol such as ethanol, butanol, butanediol and
cellulosic biofuels) and metabolites of industrial interest (e.g. organic
The bacteria, which have rare genetic and metabolic properties, are able to
manufacture these molecules from plant biomass components that other living
organisms are virtually unable to use. They can convert a large number of raw
materials (straw, wood, forestry and agricultural residues, organic, household
or industrial waste) into valuable products, utilizing their main constituents
(cellulose, hemicellulose, xylan, xylose, arabinoxylan, starch, glucose, etc.).
The patent has been co-signed by Jean-Paul Leonetti, DEINOVE's R&D Director and
CNRS senior researcher, Jacques Biton, Ivan Matic, from the Scientific Advisory
Board and Philippe Pouletty, the Chairman and cofounder of the company.
"We are delighted with the award of this broad patent, which marks an essential
stage in our roadmap," said Emmanuel Petiot, DEINOVE's Chief Executive Officer.
He added, "The invention paves the way for high-performance production systems
that are of high performance, economically viable and ecologically much more
efficient. It puts DEINOVE in pole position for an ambitious penetration of the
global market in second-generation biofuels and green chemistry with the help of
these exceptional bacteria."
For more information on patent EP2209900:
DEINOVE (Alternext Paris: ALDEI) is a cleantech company that designs and
develops new production standards based on bacteria with still untapped
Building on their unique genetic properties and extraordinary resilience,
DEINOVE optimizes the natural metabolic and fermentation capabilities of these
bacterial "micro-factories" to manufacture products that are rare or
technologically difficult to produce: second-generation biofuels (DEINOL),
chemical intermediates (DEINOCHEM), new antibiotics (through the specialist
affiliate DEINOBIOTICS SAS) and enzymes for plastic remediation (THANAPLAST(TM)
collaborative project led by CARBIOS).
DEINOVE, which has been Alternext listed since April 2010, was founded by Dr
Philippe Pouletty, Chief Executive Officer of TRUFFLE CAPITAL, and Prof.
Miroslav Radman from René Descartes University's Faculty of Medicine. It has a
workforce of thirty and conducts its R&D programmes in partnership with the CNRS
(Marseille and Montpellier), INSA (Toulouse) and VTT (Finland). DEINOVE's head
office and laboratories are located in Paris and at Technoparc Cap Alpha in
More information at www.deinove.com
Emmanuel Petiot Elisabetta Castelli
Chief Executive Officer Director of Communications and Investor Relations
Tel: + 33 142 032737 Mob: +33 613 663939
Mob: +33 626 941853
Deinove European Patent:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Deinove via Thomson Reuters ONE